EZH2 inhibitor anti-tumor activity was previously demonstrated in refractory B-cell non-Hodgkin’s lymphoma and epithelioid sarcomas60 and are currently in clinical development with tazemetostat in refractory B cell non-Hodgkin’s lymphoma (NCT03456726), CPI-1205 in advanced solid tumors (NCT03525795), and the EED inhibitor MAK-683 in diffuse large B-cell lymphoma (NCT02900651). Here, EZH2 is linked to neoplasm.